Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 100 microgram/ml - injection, solution - excipient ingredients: water for injections; mannitol; sodium bicarbonate; lactic acid - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy or dopamine agonist treatment. sandostatin treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). sandostatin is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; mannitol; lactic acid; sodium bicarbonate - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy or dopamine agonist treatment. sandostatin treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). sandostatin is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 500 microgram/ml - injection, solution - excipient ingredients: lactic acid; mannitol; sodium bicarbonate; water for injections - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy or dopamine agonist treatment. sandostatin treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). sandostatin is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - alfentanil hydrochloride, quantity: 5.44 mg (equivalent: alfentanil, qty 5 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; sodium chloride - alfentanil injection is indicated for intravenous use by specialist anaesthetists and their trainees as:,? an analgesic supplement given by incremental intravenous boluses or continuous infusion; and,? an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used.,because of its rapid onset and short duration of action, intravenous alfentanil (as hydrochloride) is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous alfentanil (as hydrochloride) is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of alfentanil (as hydrochloride) or by adapting the infusion rate.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - alfentanil hydrochloride, quantity: 1.09 mg (equivalent: alfentanil, qty 1 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride - alfentanil injection is indicated for intravenous use by specialist anaesthetists and their trainees as:,? an analgesic supplement given by incremental intravenous boluses or continuous infusion; and,? an anaesthetic induction agent where in patients undergoing in-patient surgery, when endotracheal intubation and controlled ventilation are to be used.,because of its rapid onset and short duration of action, intravenous alfentanil (as hydrochloride) is particularly suited as a narcotic analgesic for short procedures and outpatients, provided that the patients are maintained under appropriate post-operative surveillance. however, intravenous alfentanil (as hydrochloride) is also useful as an analgesic supplement for procedures of medium to long duration, since periods of very painful stimuli can be easily overcome by administration of small increments of alfentanil (as hydrochloride) or by adapting the infusion rate.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - oxycodone hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium citrate dihydrate; hydrochloric acid; citric acid monohydrate; sodium chloride; sodium hydroxide; water for injections - oxycodone hcl medsurge solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; water for injections; sodium hydroxide; hydrochloric acid; sodium citrate dihydrate - oxycodone hcl medsurge solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

medsurge pharma pty ltd - oxycodone hydrochloride, quantity: 50 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; hydrochloric acid; sodium hydroxide; sodium citrate dihydrate; water for injections - oxycodone hcl medsurge solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - lanadelumab, quantity: 300 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; dibasic sodium phosphate dihydrate; polysorbate 80; histidine; sodium chloride - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (c1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years and older.

Estats Units - anglès - NLM (National Library of Medicine)

endo pharmaceuticals inc. - oxymorphone hydrochloride (unii: 5y2ei94nbc) (oxymorphone - unii:9vxa968e0c) - oxymorphone hydrochloride 5 mg - opana is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve opana for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia opana is contraindicated in patients with: - significant respiratory depression [see warnings and precautions (5.3) ] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precautions (5.6) ] - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings and precautions (5.11) ] - hypersensitivity to oxymorphone (e.g., anaphylaxis, an